• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 15.85
  • VXN 20.63
  • VXO 18.01
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
ATHX (Athersys Inc.)
Last Trade 1.8 Dividend/Share 0 PE Ratio -10
Date May 24-2019 Dividend Yield 0.000 Return on Assets -47.34
Change -0.06 ExDividend Date 0 Return on Capital null
Bid 0 Latest EPS -0.18 Price/Sale 11.403
Ask 0 LatestEPS Date 2018-12-31 Price to Book 7.57
Volume 3593 EPS ttm -0.180 Institutional % 33.3
Avg Volume 0.94M Shares Outstanding 149.78M Insider % null
Open 1.87 Float 146.25M Short Ratio null
Prev Close 1.86 Return On Equity -67.64 5 Year Change % 0.132
High 1.92 Consensus EPS -0.09 2 Year Change % 0.241
Low 1.79 No. of Estimate 1.000 1 Year Change % -0.265
52 Week High 3.09 EPS Surprise $ null YTD Change % 0.216
52 Week Low 1.35 EPS Surprise Percent 0 6 Month Change % -0.072
52 Week Change -21.519 EBITDA 0M 3 Month Change % 0.184
50 Day MA 1.5914 Revenue 0M 1 Month Change % 0.091
200 Day MA Gross Profit 0M 5 Day Change % -0.032
Market Cap 278.58M Cash 0M 30 Day Change % 0.250
Beta 0.25732 Debt 0M Stock Exchange NASDAQ Capital Market
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products in various disease areas in the United States. Its product pipeline includes MultiStem, a novel allogeneic approach to stem cell therapy and regenerative medicine for treating a range of diseases. The company also develops orally active pharmaceutical products for the treatment of obesity and certain central nervous system disorders, including narcolepsy, excessive daytime sleepiness, and chronic fatigue, as well as other potential indications consisting of attention deficit hyperactivity disorder and other cognitive disorders, including schizophrenia. It has product co-development collaboration with Angiotech Pharmaceuticals, Inc. for the potential application of MultiStem in multiple cardiovascular indications, including myocardial infarction, peripheral vascular disease, and certain other indications. In addition, the company has a collaboration agreement with Pfizer Inc. to develop and commercialize MutiStem for the treatment of inflammatory bowel disease. Athersys, Inc. was founded in 1995 and is based in Cleveland, Ohio.